Med-IQ
Helping Your Patients Control Their Severe Asthma With Biologics

Helping Your Patients Control Their Severe Asthma With Biologics

Webcast
Online Course | Specialties: Allergy and Immunology, Family Medicine
Released: 10/21/2021
|
Expires: 10/20/2022
|
Max Credits: 1.0
Jump to Education

Faculty
Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children's Hospital
Boston, MA

Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM, CHCP
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Incorporate individual patient needs and experiences into multidimensional assessment strategies for uncontrolled asthma
  • Identify patients with moderate-to-severe asthma who may benefit from biologic treatments using available guidance and current clinical evidence
  • Employ education and communication strategies in the patient-centered management of moderate-to-severe asthma

Target Audience
This activity is intended for healthcare providers in primary care and pediatric practices, including primary care physicians, pediatricians, nurse practitioners, physician assistants, and nurses.

Statement of Need
Asthma is a complex, heterogeneous, and common respiratory disorder that affects approximately 8% of the United States population. Nearly one-half of these individuals report uncontrolled disease, resulting in substantial morbidity and serious reductions in quality of life (QOL). Wide variability in severity is seen across the asthma population and within individuals over time, with severity strongly influencing QOL, activities of daily living, social exclusion, and health outcomes. Patients with severe asthma face many challenges, including diagnostic delays, stigmatization, and misconceptions surrounding the disease; furthermore, they are often ill informed regarding asthma, disease severity, available management options, and self-management strategies. Additionally, patient-provider goals and expectations often do not align.

Although multiple evidence-based recommendations support a methodical and comprehensive approach to assessment and management, including timely referral to an asthma specialist, adherence to guidelines remains suboptimal. Moreover, many providers lack knowledge surrounding the integration of new, targeted agents into personalized approaches to asthma management.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC from the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 1.0 contact hour.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: October 21, 2021
Expiration Date: October 20, 2022
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Wanda Phipatanakul, MD, MS
Consulting fees/advisory boards: Genentech, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.

Michael Wechsler, MD
Consulting fees/advisory boards: Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.

The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Copyrighted

Abstract

Here are some key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available by clicking the "Continue" button below.

  • Asthma is a chronic inflammatory disease associated with airway hyperresponsiveness and has both short-term and long-term consequences
  • Several biologic therapies are approved to treat severe asthma, targeting multiple inflammatory pathways
  • Severe asthma requires GINA step 4 or step 5 to achieve and maintain control
  • Clinical studies have shown that all available biologic therapies result in significant reductions in asthma exacerbations and improvements in FEV, as well as exhibit similar safety profiles

View reference list.

Click "Continue" to proceed through this activity and/or receive credit.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.